Pentoxifylline
Systematic (IUPAC) name | |
---|---|
3,7-Dimethyl-1-(5-oxohexyl)-3,7-dihydro-1H-purine-2,6-dione | |
Clinical data | |
Trade names | Many names worldwide[1] |
AHFS/Drugs.com | monograph |
MedlinePlus | a685027 |
License data |
|
Pregnancy category | |
Routes of administration | Oral |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 10-30%[2] |
Metabolism | Hepatic and via erythrocytes |
Biological half-life | 0.4-0.8 hours (1-1.6 hours for active metabolite)[2] |
Excretion | Urine (95%), faeces (<4%)[2] |
Identifiers | |
CAS Number | 6493-05-6 |
ATC code | C04AD03 (WHO) |
PubChem | CID 4740 |
IUPHAR/BPS | 7095 |
DrugBank | DB00806 |
ChemSpider | 4578 |
UNII | SD6QCT3TSU |
KEGG | D00501 |
ChEMBL | CHEMBL628 |
Chemical data | |
Formula | C13H18N4O3 |
Molar mass | 278.31 g/mol |
| |
| |
(verify) |
Pentoxifylline (INN, BAN, USAN) or oxpentifylline (AAN)[3] is a drug used to treat muscle pain in people with peripheral artery disease.[4] It is generic and sold under many brand names worldwide.[1]
Medical uses
Its primary use in medicine is in treating the symptoms of muscle pain resulting from peripheral artery disease.[4] This is its only FDA, MHRA and TGA-labelled indication.[3][5][6]
Adverse effects
Dizziness, headache, nausea, vomiting, indigestion and flushing are common side effects. Uncommon and rare side effects include angina, palpitations, hypersensitivity, itchiness, rash, hives, bleeding, hallucinations, arrhythmias, and aseptic meningitis.[2][3][5][6]
Contraindications include intolerance to pentoxifylline or other xanthine derivatives, recent retinal or cerebral haemorrhage, and risk factors for haemorrhage.[2]
Co-administration of pentoxifylline and sodium thiopental may cause death by acute pulmonary edema in rats.[7]
Mechanism
Like other methylated xanthine derivatives, pentoxifylline is a competitive nonselective phosphodiesterase inhibitor[8] which raises intracellular cAMP, activates PKA, inhibits TNF[9][10] and leukotriene [11] synthesis, and reduces inflammation and innate immunity.[11] In addition, pentoxifylline improves red blood cell deformability (known as a haemorrheologic effect), reduces blood viscosity and decreases the potential for platelet aggregation and thrombus formation.[12] Pentoxifylline is also an antagonist at adenosine 2 receptors.[13]
Effect of Pentoxifylline on seizure
In a study, the effect of pentoxifylline as a phosphodiestrase inhibitor was study on the pentylenetetrazol-induced seziure in the wild-type mice. Pentoxifylline in that study reduced the anti-convulsive effect of H-89 and reduced the seizure threshold.[14]
Research
There is some evidence that pentoxifyllinenon can lower the levels of some biomarkers in non-alcoholic steatohepatitis but evidence is insufficient to determine if the drug is safe and effective for this use.[15]
See also
- Lisofylline, an active metabolite of pentoxifylline
- Propentofylline
References
- 1 2 Drugs.com drugs.com international listings for Pentoxifylline. Page accessed Feb 1, 206
- 1 2 3 4 5 "Trental, Pentoxil (pentoxifylline) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Retrieved 3 February 2014.
- 1 2 3 "PRODUCT INFORMATION TRENTAL® 400" (PDF). TGA eBusiness Services. sanofi-aventis australia pty limited. 25 March 2010. Retrieved 3 February 2014.
- 1 2 Salhiyyah K, Senanayake E, Abdel-Hadi M, Booth A, Michaels JA (2012). "Pentoxifylline for intermittent claudication". The Cochrane Database of Systematic Reviews 1: CD005262. doi:10.1002/14651858.CD005262.pub2. PMID 22258961.
- 1 2 "PENTOXIFYLLINE tablet, extended release [Apotex Corp.]". DailyMed. Apotex Corp. February 2013. Retrieved 3 February 2014.
- 1 2 "Trental 400 - Summary of Product Characteristics (SPC)". electronic Medicines Compendium. Sanofi. 10 October 2013. Retrieved 3 February 2014.
- ↑ Pereda J, Gómez-Cambronero L, Alberola A, Fabregat G, Cerdá M, Escobar J, Sabater L, García-de-la-Asunción J, García-de-la-Asuneión J, Viña J, Sastre J (2006). "Co-administration of pentoxifylline and thiopental causes death by acute pulmonary oedema in rats". British Journal of Pharmacology 149 (4): 450–5. doi:10.1038/sj.bjp.0706871. PMC 1978439. PMID 16953192.
- ↑ Essayan DM (2001). "Cyclic nucleotide phosphodiesterases". The Journal of Allergy and Clinical Immunology 108 (5): 671–80. doi:10.1067/mai.2001.119555. PMID 11692087.
- ↑ Deree J, Martins JO, Melbostad H, Loomis WH, Coimbra R (2008). "Insights into the regulation of TNF-alpha production in human mononuclear cells: the effects of non-specific phosphodiesterase inhibition". Clinics 63 (3): 321–8. doi:10.1590/S1807-59322008000300006. PMC 2664230. PMID 18568240.
- ↑ Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U (1999). "Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages". American Journal of Respiratory and Critical Care Medicine 159 (2): 508–11. doi:10.1164/ajrccm.159.2.9804085. PMID 9927365.
- 1 2 Peters-Golden M, Canetti C, Mancuso P, Coffey MJ (2005). "Leukotrienes: underappreciated mediators of innate immune responses". Journal of Immunology 174 (2): 589–94. doi:10.4049/jimmunol.174.2.589. PMID 15634873.
- ↑ Ward A, Clissold SP (1987). "Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy". Drugs 34 (1): 50–97. doi:10.2165/00003495-198734010-00003. PMID 3308412.
- ↑ Rodríguez-Morán M, Guerrero-Romero F (2008). "Efficacy of pentoxifylline in the management of microalbuminuria in patients with diabetes". Current Diabetes Reviews 4 (1): 55–62. doi:10.2174/157339908783502343. PMID 18220696.
- ↑ Hosseini-Zare MS, Salehi F, Seyedi SY, Azami K, Ghadiri T, Mobasseri M, Gholizadeh S, Beyer C, Sharifzadeh M (2011). "Effects of pentoxifylline and H-89 on epileptogenic activity of bucladesine in pentylenetetrazol-treated mice". European Journal of Pharmacology 670 (2-3): 464–70. doi:10.1016/j.ejphar.2011.09.026. PMID 21946102.
- ↑ Li W, Zheng L, Sheng C, Cheng X, Qing L, Qu S (2011). "Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease". Lipids in Health and Disease 10: 49. doi:10.1186/1476-511X-10-49. PMC 3088890. PMID 21477300.
External links
|
|